

# Planned filings 2013 to ≥ 2017

2013	2014	2015	2016	≥ 2017	
<b>AIN457</b> Psoriasis	<b>AFQ056</b> Fragile X syndrome	<b>BKM120</b> Breast cancer	<b>BYM338</b> sIBM <sup>11</sup>	<b>ATI355</b> Spinal cord injury	<b>QAW039</b> Asthma
<b>LCZ696</b> Hypertension	<b>LBH589</b> Multiple Myeloma	<b>MEK162</b> NRAS Mutant Melanoma	<b>CTL019</b> Leukemia	<b>AUY922</b> Solid tumors	<b>QAX576</b> Allergic Diseases
<b>RLX030*</b> Acute heart failure	<b>LCQ908</b> FCS <sup>3</sup>	<b>PKC412</b> AML <sup>6</sup>	<b>LCI699</b> Cushing's	<b>BAF312</b> Multiple sclerosis	<b>QGE031</b> Allergic diseases
<b>Signifor® LAR<sup>1</sup></b> Acromegaly	<b>LDE225</b> Basal cell carcinoma	<b>Afinitor®</b> DLBCL <sup>7</sup>	<b>LGX818</b> BRAF Mutant Melanoma	<b>BCT197</b> COPD <sup>17</sup>	<b>AIN457</b> Multiple sclerosis
<b>Xolair®</b> CSU <sup>2</sup>	<b>LDK378</b> NSCLC <sup>4</sup>	<b>Afinitor®</b> Non-functioning GI and Lung NET <sup>8</sup>	<b>MEK162 + LGX818</b> BRAF Mutant Melanoma	<b>BEZ235</b> Solid tumors	<b>AIN457</b> Uveitis
	<b>Afinitor®</b> HER2+ Breast cancer 1 <sup>st</sup> Line	<b>Afinitor®</b> TSC Seizure	<b>TKI258</b> Solid tumors	<b>BGJ398</b> Solid tumors	<b>BKM120</b> Solid tumors
	<b>Afinitor®</b> HER2+ Breast cancer 2 <sup>nd</sup> /3 <sup>rd</sup> Line	<b>Gilenya®</b> PPMS <sup>9</sup>	<b>ACZ885</b> Sec. Prev. CV events <sup>12</sup>	<b>BGS649</b> OHH <sup>18</sup>	<b>BYM338</b> Hip Fracture
	<b>AIN457</b> Rheumatoid arthritis	<b>PKC412</b> ASM <sup>10</sup>	<b>Gilenya®</b> CIDP <sup>13</sup>	<b>BYL719</b> Solid tumors	<b>LCZ696</b> Heart failure (PEF) <sup>19</sup>
	<b>AIN457</b> Ankylosing spondylitis	<b>Signifor® LAR<sup>1</sup></b> Cushing's	<b>Lucentis®</b> CNV and ME <sup>14</sup>	<b>CAD106</b> Alzheimer's	<b>LDE225</b> Solid tumors
	<b>AIN457</b> Psoriatic arthritis		<b>MEK162</b> LGSOC <sup>15</sup>	<b>DEB025</b> HCV infection	<b>LGX818</b> Solid tumors
	<b>Jakavi®</b> Polycythemia vera		<b>Tekturna®</b> Heart failure <sup>16</sup>	<b>KAE609</b> Malaria	<b>MEK162</b> Solid tumors
	<b>LCZ696</b> Heart failure (REF) <sup>5</sup>			<b>LFF571</b> Cl.difficile infections	<b>Tasigna</b> CML Treatment free remission
				<b>LJM716</b> Solid Tumors	<b>QMF149</b> COPD <sup>17</sup>
				<b>LIK066</b> Type II diabetes	<b>QMF149</b> Asthma

\* Submitted EU December 2012

New molecule
New indication
New formulation

- 1 Long-acting release
- 2 Chronic spontaneous urticaria
- 3 Familial chylomicronemia syndrome
- 4 Non small cell lung cancer
- 5 Reduced ejection fraction
- 6 Acute myeloid leukemia
- 7 Diffuse large B-cell lymphoma
- 8 Neuroendocrine tumors
- 9 Primary progressive multiple sclerosis
- 10 Aggressive systemic mastocytosis
- 11 Sporadic inclusion body myositis
- 12 Secondary prevention of cardiovascular events

- 13 Chronic inflammatory demyelinating polyneuropathy
- 14 Choroidal neovascularization (CNV) and macular edema (ME) secondary to conditions other than age related macular degeneration, diabetic macular edema, Retinal vein occlusion and pathologic myopia
- 15 Low-grade serous ovarian cancer
- 16 Reduction of CV death/hospitalization in chronic heart failure patients
- 17 Chronic obstructive pulmonary disease
- 18 Obese hypogonadotropic hypogonadism
- 19 Preserved ejection fraction